Intellia Therapeutics (NTLA) Competitors $11.40 +0.05 (+0.44%) Closing price 09/2/2025 04:00 PM EasternExtended Trading$11.52 +0.12 (+1.01%) As of 09:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NTLA vs. BEAM, CRSP, EDIT, TWST, TGTX, CYTK, ACAD, KRYS, TLX, and ADMAShould you be buying Intellia Therapeutics stock or one of its competitors? The main competitors of Intellia Therapeutics include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Twist Bioscience (TWST), TG Therapeutics (TGTX), Cytokinetics (CYTK), ACADIA Pharmaceuticals (ACAD), Krystal Biotech (KRYS), Telix Pharmaceuticals (TLX), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Intellia Therapeutics vs. Its Competitors Beam Therapeutics CRISPR Therapeutics Editas Medicine Twist Bioscience TG Therapeutics Cytokinetics ACADIA Pharmaceuticals Krystal Biotech Telix Pharmaceuticals ADMA Biologics Intellia Therapeutics (NASDAQ:NTLA) and Beam Therapeutics (NASDAQ:BEAM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation. Is NTLA or BEAM more profitable? Beam Therapeutics has a net margin of -661.31% compared to Intellia Therapeutics' net margin of -908.48%. Beam Therapeutics' return on equity of -43.15% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Intellia Therapeutics-908.48% -57.48% -45.04% Beam Therapeutics -661.31%-43.15%-31.06% Do analysts prefer NTLA or BEAM? Intellia Therapeutics presently has a consensus target price of $29.05, indicating a potential upside of 154.85%. Beam Therapeutics has a consensus target price of $48.45, indicating a potential upside of 197.08%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than Intellia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intellia Therapeutics 1 Sell rating(s) 6 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.58Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 3 Strong Buy rating(s) 3.07 Which has higher valuation and earnings, NTLA or BEAM? Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntellia Therapeutics$57.88M21.14-$519.02M-$4.69-2.43Beam Therapeutics$63.52M25.97-$376.74M-$4.50-3.62 Does the media favor NTLA or BEAM? In the previous week, Intellia Therapeutics had 4 more articles in the media than Beam Therapeutics. MarketBeat recorded 11 mentions for Intellia Therapeutics and 7 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 1.64 beat Intellia Therapeutics' score of 1.52 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 11 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Beam Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do insiders & institutionals have more ownership in NTLA or BEAM? 88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 3.1% of Intellia Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, NTLA or BEAM? Intellia Therapeutics has a beta of 2.28, meaning that its share price is 128% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500. SummaryBeam Therapeutics beats Intellia Therapeutics on 13 of the 17 factors compared between the two stocks. Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NTLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NTLA vs. The Competition Export to ExcelMetricIntellia TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.22B$3.10B$5.77B$9.76BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-2.4320.8683.0526.39Price / Sales21.14391.41527.23108.99Price / CashN/A43.5325.7028.92Price / Book1.718.1011.006.58Net Income-$519.02M-$53.35M$3.28B$265.84M7 Day Performance-0.18%-0.29%-0.19%-0.26%1 Month Performance-0.78%9.18%8.33%5.82%1 Year Performance-47.27%10.11%53.31%22.47% Intellia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NTLAIntellia Therapeutics4.7465 of 5 stars$11.40+0.4%$29.05+154.8%-49.2%$1.22B$57.88M-2.43600Positive NewsBEAMBeam Therapeutics2.3741 of 5 stars$16.44-1.2%$48.45+194.7%-38.9%$1.66B$63.52M-3.65510News CoveragePositive NewsCRSPCRISPR Therapeutics3.6013 of 5 stars$54.13-0.3%$71.60+32.3%+10.4%$4.92B$35M-9.97460Analyst RevisionEDITEditas Medicine4.0389 of 5 stars$2.72-2.9%$5.10+87.5%-34.0%$244.58M$38.90M-0.95230News CoverageTWSTTwist Bioscience3.9012 of 5 stars$27.39-4.2%$49.40+80.4%-39.3%$1.65B$312.97M-18.89990News CoveragePositive NewsTGTXTG Therapeutics4.5702 of 5 stars$28.53-3.1%$46.25+62.1%+26.6%$4.53B$454.07M77.11290Positive NewsCYTKCytokinetics4.1263 of 5 stars$37.01-3.5%$71.58+93.4%-13.1%$4.43B$18.47M-7.26250Trending NewsAnalyst ForecastInsider TradeOptions VolumeGap UpACADACADIA Pharmaceuticals4.0488 of 5 stars$25.32-1.6%$28.88+14.0%+54.9%$4.27B$1.02B19.04510News CoverageAnalyst RevisionKRYSKrystal Biotech4.8211 of 5 stars$146.77-2.5%$210.38+43.3%-23.6%$4.25B$359.21M29.83210Positive NewsTLXTelix PharmaceuticalsN/A$12.20-2.2%$22.33+83.1%N/A$4.13B$516.72M0.00N/AAnalyst RevisionHigh Trading VolumeADMAADMA Biologics4.0125 of 5 stars$17.01-4.4%$27.67+62.6%-0.6%$4.06B$474.17M19.78530Positive News Related Companies and Tools Related Companies Beam Therapeutics Alternatives CRISPR Therapeutics Alternatives Editas Medicine Alternatives Twist Bioscience Alternatives TG Therapeutics Alternatives Cytokinetics Alternatives ACADIA Pharmaceuticals Alternatives Krystal Biotech Alternatives Telix Pharmaceuticals Alternatives ADMA Biologics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NTLA) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NTLA Stock Alerts